- Home
- KRKR vs XBIO Comparison
KRKR vs XBIO Comparison
Compare KRKR & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- XBIO
- Stock Information
- Founded
- KRKR 2010
- XBIO N/A
- Country
- KRKR China
- XBIO United States
- Employees
- KRKR N/A
- XBIO N/A
- Industry
- KRKR Business Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KRKR Consumer Discretionary
- XBIO Health Care
- Exchange
- KRKR Nasdaq
- XBIO Nasdaq
- Market Cap
- KRKR 6.6M
- XBIO 6.3M
- IPO Year
- KRKR 2019
- XBIO N/A
- Fundamental
- Price
- KRKR $3.22
- XBIO $4.09
- Analyst Decision
- KRKR
- XBIO Hold
- Analyst Count
- KRKR 0
- XBIO 1
- Target Price
- KRKR N/A
- XBIO N/A
- AVG Volume (30 Days)
- KRKR 22.3K
- XBIO 24.1K
- Earning Date
- KRKR 12-31-2024
- XBIO 11-12-2024
- Dividend Yield
- KRKR N/A
- XBIO N/A
- EPS Growth
- KRKR N/A
- XBIO N/A
- EPS
- KRKR N/A
- XBIO N/A
- Revenue
- KRKR $41,654,350.00
- XBIO $2,523,427.00
- Revenue This Year
- KRKR $45.99
- XBIO N/A
- Revenue Next Year
- KRKR $31.46
- XBIO N/A
- P/E Ratio
- KRKR N/A
- XBIO N/A
- Revenue Growth
- KRKR N/A
- XBIO 7.15
- 52 Week Low
- KRKR $2.76
- XBIO $2.78
- 52 Week High
- KRKR $12.60
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- KRKR 52.25
- XBIO 55.58
- Support Level
- KRKR $3.10
- XBIO $3.94
- Resistance Level
- KRKR $3.69
- XBIO $4.31
- Average True Range (ATR)
- KRKR 0.35
- XBIO 0.24
- MACD
- KRKR 0.06
- XBIO -0.01
- Stochastic Oscillator
- KRKR 70.43
- XBIO 52.28
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.